Latest

T cells that react to a Parkinson’s disease-linked protein have an early, unique, and detectable gene signature.

Chemical biologist Stefano Tiziani uses metabolomics to identify new combination cancer treatments and to predict which patients will respond best to chemotherapy.

A biotech start-up teamed up with technology giants like Apple to continuously monitor people with Parkinson’s disease so that they could personalize their treatments in the clinic and the lab.